Veracyte Inc VCYT:NASDAQ

Last Price$30.15NASDAQ Previous Close - Last Trade as of 3:59PM ET 1/17/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$30.15 (4)
Ask (Size)$35.35 (1)
Day Low / HighN/A - N/A
Volume345.0 K
 

View Biotechnology IndustryPeer Comparison as of 01/17/2020

 

Veracyte Inc ( NASDAQ )

Price: $30.15
Change: -0.02 (0.07%)
Volume: 345.0 K
3:59PM ET 1/17/2020
 
 

Alector Inc ( NASDAQ )

Price: $21.38
Change: +1.49 (7.49%)
Volume: 568.4 K
4:00PM ET 1/17/2020
 
 

Dicerna Pharmaceuticals Inc ( NASDAQ )

Price: $21.36
Change: +0.18 (0.83%)
Volume: 544.9 K
4:00PM ET 1/17/2020
 
 

Esperion Therapeutics Inc ( NASDAQ )

Price: $57.43
Change: -1.04 (1.78%)
Volume: 388.0 K
3:59PM ET 1/17/2020
 
 

NextCure Inc ( NASDAQ )

Price: $50.12
Change: -2.78 (5.26%)
Volume: 231.3 K
4:00PM ET 1/17/2020
 

Read more news Recent News

Insider Trends: Insider Sales Extend 90-Day Trend at Veracyte
4:56PM ET 1/15/2020 MT Newswires

On Jan 14, 2020, Director, Evan Jones, executed a sale of 5,000 shares in Veracyte (VCYT) for $142,521. After the Form 4 filing with the SEC, Jones...

Veracyte, AstraZeneca's Acerta Pharma Pursue Collaboration
8:48AM ET 1/08/2020 MT Newswires

Veracyte (VCYT) said pre-market Wednesday that it has entered into a multi-year collaboration with Acerta Pharma, the hematology research and development...

Insider Trends: Insider Prolongs 90-Day Selling Trend at Veracyte
4:39PM ET 12/18/2019 MT Newswires

Evan Jones, Director, reported a sale of 15,000 shares in Veracyte (VCYT) on Dec 17, 2019, for $438,866. Following the Form 4 filing with the SEC, Jones...

Insider Trends: Insider Sale Eases Back 90-Day Buy Trend at Veracyte
4:21PM ET 12/09/2019 MT Newswires

Evan Jones, Director, on Dec 05, 2019, sold 5,951 shares in Veracyte (VCYT) for $178,558. Jones, subsequent to the transactions disclosed in the SEC Form...

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Phone+1.650.243.6300
Number of Employees270
Recent SEC Filing01/15/20204
Chairman & Chief Executive OfficerBonnie H. Anderson
Chief Operating & Financial OfficerKeith Kennedy
Chief Scientific & Medical OfficerGiulia C. Kennedy
Chief Information OfficerAshish Kheterpal

Company Highlights

Price Open$30.48
Previous Close$30.17
52 Week Range$15.82 - 31.18
Market Capitalization$1.5 B
Shares Outstanding48.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.19
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-7.08%
Return on Equity-5.33%

Analyst Ratings as of 07/31/2019

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset